Valneva and LimmaTech Announce First Vaccination in Phase 2b Human Challenge Study of Tetravalent Shigella Vaccine Candidate S4V2
S4V2 will be tested for safety and preliminary efficacy in approximately 120 healthy Shigella -naïve participants aged 18 to 50 years at three sites in the United States. The study, sponsored and ...
Allianz Sees Profit at Top of Forecast After Strong Quarter
Allianz SE, the German insurer that owns Pacific Investment Management Co., slightly lifted its guidance for full-year profit ...